Mission
The mission of Alzheimer’s Association is to eliminate Alzheimer’s disease through the advancement of research, to provide and enhance care and support for all affected, and to reduce the risk of dementia through the promotion of brain health.

Strategy/Approach
The Alzheimer’s Association is the world’s leading voluntary health organization in Alzheimer’s care, support and research. It is the only organization with the reach, magnitude and drive to achieve a vision of a world without Alzheimer’s disease. The Association furthers its mission by:

- **Advancing Research** – Largest nonprofit funder of Alzheimer’s research. Through partnerships and funded projects, the Association has been a part of every major research advancement during the past 30 years. Its peer-reviewed research grant program has awarded more than $3.15 billion to over 2,200 proposals. In fiscal year 2013, the Alzheimer’s Association International Research Grant Program awarded more than $14.8 million in funding to 75 investigators.

- **Enhancing Care and Support** – Global, national and local initiatives to enhance care and support for all those affected by Alzheimer’s and other dementias. Outreach efforts include local chapters across the nation, a 24/7 helpline, a clinical trial matching service, support groups, education programs and safety services. In fiscal year 2013, the Alzheimer’s Association provided services and support to 2.6 million individuals.

- **Advocacy** – The Association rallied thousands of advocates to ensure the passage of the National Alzheimer’s Project Act, establishing the National Plan to Address Alzheimer’s Disease, and continues to work on behalf of all those affected by the disease to achieve effective implementation of the plan. To do so, the Association executes strategies to develop relationships with state and federal policymakers, mobilizes Alzheimer’s advocates, and coordinates activities with a sister organization, the Alzheimer’s Impact Movement.

- **Increasing Concern and Awareness of the Disease and the Association** – Continue to strengthen the momentum of the Alzheimer’s movement by increasing concern of the disease and awareness of the Association among a targeted audience by 50 percent. Build constituent engagement through activities to support all strategic objectives.

- **Growing Revenue Support of the Mission** – Achieve significantly greater Association-wide mission impact by growing contributed revenue by an average of 8 percent per year. Tactics include the development of an Association-wide philanthropic culture that fully embraces partnerships, fundraising and revenue growth as priorities.

Research Portfolio
The Alzheimer’s Association funds a wide variety of investigations by scientists at every stage of their careers. Each grant is designed to meet the needs of the field and to introduce fresh ideas in Alzheimer's research. The association funds investigations that advance understanding of Alzheimer's disease, identify new treatment strategies, improve care for people with dementia and optimize services for their families, and further knowledge of brain health and disease prevention.

Funding opportunities include:

- **New Investigator Research Grant** – Funds the next generation of promising scientists who have earned their doctoral degrees within the last 10 years.
  - Up to $100,000 over two years

- **New Investigator Research Grant to Promote Diversity** – Funds new investigators from diverse backgrounds with intent to support early-career development that will lay groundwork for future research grants.
  - Up to $100,000 over two years

- **Mentored New Investigator Research Grant to Promote Diversity** – Funds mentored research conducted by underrepresented researchers who have earned their doctoral degrees within the last 10 years.
  - Up to $150,000 over two to three years

- **Zenith Fellows Award Program**—Competition to provide major support for investigators who have contributed significantly to the field of Alzheimer’s research, made significant contributions to other areas of science and are now focusing more directly on problems related to Alzheimer’s disease, and are likely to make substantial contributions in the future.
  - Up to $450,000 over three years

- **US-UK Young Investigator Exchange Fellowship**—Funds research into the causes, diagnosis, and treatment of Alzheimer’s disease and encourages promising scientists as they establish international Alzheimer’s research careers.
  - Up to $300,000 over 3 years
Funding is peer-reviewed by an international network of volunteer scientists and quality-assured by a Medical and Scientific Advisory Council.

**Partnership Practices**

The Alzheimer's Association creates partnerships throughout the scientific community to propel the field of Alzheimer's research forward. The Association brings together government, industry, and academia to increase funding and accelerate discovery.

Key partnerships:

- The Alzheimer’s Association is a steering committee member of the Accelerating Medicines Partnership, an initiative uniting biopharmaceutical companies, the National Institutes of Health, the Food and Drug Administration, and other advocacy groups. Together, we are creating a new model of collaboration to develop diagnostics and treatments.
- The Association works with the Laboratory of Neuro Imaging at University of Southern California, University of Geneva and NeuGrid, and Intel Corporation to host the Global Alzheimer's Association Interactive Network (GAAIN), a cloud-enabled database for Alzheimer's research. Researchers worldwide have free-of-charge access to a vast repository of data featuring sophisticated analytical tools and massive computational power enabling researchers worldwide to formulate and answer complex scientific questions.
- Global Consortium for Biomarker Standardization Project: A private-public partnership aimed at accelerating the development of biological changes or “biomarkers,” which have the potential to measure the physical changes in the brain associated with Alzheimer's and help track the progression of the disease. This is a partnership of governmental agencies, industry and academic partners, and advocacy organizations.
- The Association convenes the Alzheimer’s Association Research Roundtable of over 25 industry leaders twice a year to facilitate the development of new treatments and overcome obstacles to scientific discovery. Meetings include thought leaders from industry, academia and regulatory agencies.
- The Association is a major sponsor of Alzheimer’s Disease Neuroimaging Initiative (ADNI), a field-wide collaboration to standardize brain imaging procedures, ensuring that images obtained by different researchers at various locations will capture the same medical and scientific information. The Association collaborated with industry leaders (e.g., Abbott, Bayer Schering Pharma AG, Bioclinica Inc., Biogen Idec, Eisai Global Clinical Development, Elan Corporation, Genentech, Takeda Pharmaceuticals, etc.) and other nonprofit partners to support this initiative.
- International Alzheimer’s Disease Research Portfolio (IADRP): A collaborative project between the Alzheimer’s Association, National Institutes of Health (NIH) and other international organizations that provide funding to support Alzheimer’s research.
- Other partners include: Alzheimer’s Study Group, American Academy of Neurology Foundation, Animal Model Consortium, Centers for Disease Control and Prevention’s Healthy Brain Initiative, Global Down Syndrome Foundation, Health Research Alliance, Linda Crnic Institute for Down Syndrome, Michael J. Fox Foundation, Multi Domain Interventional Trials for Memory Disorders, and the Working Group on Technology.

**Financials**

The Alzheimer’s Association is a 501(c)(3) tax-exempt nonprofit organization. The most recent financial information available is from 2013.¹

Year ending 6/30/13:

- Revenue: $123,675,000
- Assets: $139,052,000
- Grants paid: $14,800,000
- Gifts received: $110,865,000
- Expenditures: $114,333,000

**Key Accomplishments**

- Committed more than $315 million to more than 2,200 best-of-field grant proposals since 1982. In fiscal year 2013 alone, the International Research Grant Program awarded more than $14.8 million to 75 investigators. This program has led to exciting advances, including the development of Pittsburgh Compound B (PIB), the first radiotracer capable of showing beta-amyloid in the living brain during a PET scan.
- Annually, hosts the Alzheimer’s Association International Conference® to accelerate global information exchange among more than 5,000 members of the dementia medical and scientific research community. The conference is a launching point for major milestones in the field, including new diagnostic tools, the results of drug trials, and information on risk factors.
- Provided critical early funding of the Dominantly Inherited Alzheimer’s Network Trials Unit (DIAN TU), the first-ever anti-amyloid Alzheimer’s prevention trial, and enabled the study to start a year earlier than planned.
- In July 2012, launched the Alzheimer’s Association TrialMatch®, a confidential, free and interactive tool that provides an individualized clinical trial matching service for people with Alzheimer's disease and other dementias to participate in these studies. In fiscal year 2013, more than 20,000 people initiated profiles through the service in order to find a match based on their personal criteria and location.
- As the loudest voice demanding Congress to make Alzheimer’s a national priority, the Association created a petition calling for a strong national

¹ Information obtained from Alzheimer’s Association Annual Report alz.org/annualreport
Alzheimer’s plan to help all Americans affected by the disease. The petition, signed by nearly a quarter of a million Americans, was submitted to President Obama, who signed the National Alzheimer’s Project Act into law. The Association continues to work with state and federal policymakers, in addition to 600,000 advocates across the country, to ensure that the resources are in place to meet the plan’s goal of finding methods of treatment and prevention by 2025.

- In fiscal year 2013, the Alzheimer’s Association provided services and support to 2.6 million individuals affected by Alzheimer’s disease. The Alzheimer’s Association website, alz.org, and the nationwide 24/7 Helpline (800.272.3900) serve as year-round entry points to the organization’s network of resources, including care consultation, support groups, education programs, early-stage initiatives and safety services.

**Leadership**
The association is governed by a Board of Directors and supported by a permanent staff.

- **President and CEO:** Harry Johns, harry.johns@alz.org
- **Chief Strategy Officer:** Angela Geiger, angela.geiger@alz.org
- **Vice President, Medical and Scientific Affairs:** Maria Carrillo, maria.carrillo@alz.org
- **Vice President, Public Policy and Advocacy:** Robert J. Egge, robert.egge@alz.org

**Other Information**
**Advocacy/Public Policy Office**
1212 New York Avenue, NW
Suite 800
Washington, DC 2005-6105
202.393.7737
advocate@alz.org